Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Intermediate Filaments01:31

Types of Intermediate Filaments

3.7K
The intermediate filaments are an essential component of the cytoskeleton. Presently six types of intermediate filament have been identified. Type I and II are acidic and basic keratin proteins. Type III is of mesodermal origin and comprises four proteins: vimentin, desmin, glial fibrillary acidic protein (GFAP), and peripherin. Vimentin is commonly found in mesenchymal cells, desmin in muscle cells, GFAP in astrocytes, while peripherin is found in peripheral nervous system neurons (PNS). Type...
3.7K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Idh1 And Idh2 Gene Mutations In Omani Patients With Acute Myeloid Leukemia: Prognostic Significance And Clinic-pathologic Features.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Idh1 And Idh2 Gene Mutations In Omani Patients With Acute Myeloid Leukemia: Prognostic Significance And Clinic-pathologic Features.

Related Experiment Video

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

IDH1 and IDH2 Gene Mutations in Omani Patients with Acute Myeloid Leukemia: Prognostic Significance and Clinic-pathologic Features.

Yusra Al Abri1, Mohammed Al Huneini2, Shoaib Al Zadjali3

  • 1Hematopathology Residency Training Program, Oman Medical Specialty Board, Muscat, Oman.

Oman Medical Journal
|July 26, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Isocitrate dehydrogenase (IDH) mutations in acute myeloid leukemia (AML) are linked to a poor prognosis. This study found IDH mutations in 11.5% of Omani AML patients, with comparable treatment responses but poorer overall survival.

Keywords:
Acute Myeloid LeukemiaIDH2 Protein, HumanIsocitrate Dehydrogenase 1

More Related Videos

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

302
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.8K

Related Experiment Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

302
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.8K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Isocitrate dehydrogenase (IDH) mutations are increasingly recognized as significant drivers in various cancers, including acute myeloid leukemia (AML).
  • Understanding the prevalence and clinical impact of IDH mutations is crucial for developing targeted therapies and improving patient outcomes in AML.

Purpose of the Study:

  • To determine the prevalence of isocitrate dehydrogenase (IDH) mutations (IDH1 and IDH2) in Omani patients with acute myeloid leukemia (AML).
  • To evaluate the clinicopathologic impact of IDH mutations on AML characteristics and patient prognosis.
  • To assess the effect of IDH mutations on treatment response and overall survival in AML patients.

Main Methods:

  • A retrospective cohort study of 61 Omani AML patients treated at Sultan Qaboos University Hospital between 2009 and 2019.
  • Direct polymerase chain reaction (PCR) product sequencing was used to screen for IDH1 and IDH2 mutations at diagnosis.
  • Statistical analyses, including log-rank tests for survival, were performed using SPSS software.

    • Main Results:

    • IDH mutations were identified in 11.5% of the study cohort (IDH1 R132: 6.6%, IDH2 R140: 3.3%, IDH2 R172: 1.6%).
    • IDH mutations were associated with older age, lower white blood cell count, higher platelet counts, normal karyotype AML, and intermediate cytogenetic risk.
    • Patients with IDH mutations had a poor overall survival (median OS of 9 months), although response rates were comparable to IDH wild-type AML.

    Conclusions:

    • The prevalence and clinicopathologic associations of IDH mutations in Omani AML patients align with international findings, highlighting their role in disease progression.
    • IDH mutations confer a poor prognosis in AML, underscoring the need for further investigation into targeted therapies like selective IDH inhibitors.
    • This study provides contemporary data on IDH mutations in AML, valuable for comparing outcomes with emerging treatment strategies.